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4th generation cephalosporins: 
Microbiological rationale and clinical 
perspectives 
P-lactamase-mediated resistance in hospital 
pathogens 
R.N. Jones. University OfIowa, IA, USA 
Resistance in Gram-negative bacteria is frequently mediated by 
/3-lactamase production. The four major p u p s  currently recog- 
nised on the basis of amino acid sequence (A to D) include 3 with a 
serine active site (A, C and D). Class A includes the common TEM 
enzymes, class B the metallo B-lactamases which coder resistance 
to carbapenems, class C the AmpC chromosomal cephalosporinases 
and class D the OXA and PSE enzymes which have p e n i c b  as 
the preferred substrate. Of particular concern are inducible AmpC 
/3-lactamases, found in Enterobacter, Citrobacter, Serratia, Pseudomom, 
Morganella and Providenn'a spp. and which confer resistance (sta- 
bly de-repressed mutants) to 3d generation cephalosporins (3GCs). 
These pathogens are fiequent causes of nosocomial infection and 
pose an enormous therapeutic challenge to the chician. Resistance 
can emerge on treatment. Infections caused by Enterobacter have in- 
creased during the 1990s: thls pathogen was responsible for 6.3% of 
all mfections in a US survey conducted in 1994, and is the fourth 
most prevalent cause of nosocormal RTI. In Europe and the Far East 
(1987-91), up to 40% of isolates of Enterobncrer cloarae and Citrob- 
jeundii produced stably depressed AmpC /3-lactamases. T ~ I S  increase 
in resistance to 3 GCs has been correlated with increased use of 
some broad spectrum antimicrobials such as ceftazidime. Both 3GCs 
and carbapenems are potent inducers of AmpC, but 4th generation 
cephalosporins such as cefpirome and cefepime have low induction 
potential and &ty for the enzyme. In addition, their high mem- 
brane penetration rates and /3-lactamase stability make them valuable 
treatment options as resistance increases in the hospital environment. 
Extended-spectrum /3-lactamases are also increasing in prevalence. 
Changing epidemiology of severe nosocomial 
infections 
D. Pittet. Hopital Cantonal Universitaire, Geneva, Switzerland 
In the setting of the ICU, data on the epidemiology of severe infec- 
tion are used to monitor the effect of preventive measures and pol- 
icy changes. The chance of contracting infection correlates with MI- 
ious risk factors including length of stay, antibacterial usage, catheter- 
isation, mechanical ventilation and use of invasive devices. Infection 
can be classified as community- or hospital-acquired, and early or 
late in onset. Most early onset infection (5 4 days) is associated with 
S. pneumoniae or other streptococci, H. Injuenzae, enterobacteria or 
MSSA. Late onset infection (r 4 days) is associated with Enferoboc- 
ter spp., Smatia spp., Pseudomom spp., Acinetobacter spp., enterococci, 
MRSA and fungi, and is consequently more &cult to treat. A twelve 
year (1980-1992) study including 260,834 patients in the USA has 
confirmed the increase in Gram-positive pathogens at the expense 
of Gram-negatives, particularly as causal agents of bacteremia, al- 
though some new and d&cult-treat Gram-negatives are emerging, 
e.g. Srenotrophomom. Treatment of severe nosocormal mfections re- 
mains mostly empirical, and with the increase of resistance to existing 
agents, alternatives are needed. Carbapenems are powerful antibacte- 
rials, but the emergence of metallo /3-lactamases is of concern. 4'h 
generation cephalosporins, e.g. cefpirome and cefipime, hold promise 
in view of their broad spectrum, stability to most 6-lactamases and 
enhanced Gram-positive activity. Carefully designed cllnical trials are 
mandatory to assess the respective advantages and impact on host flora 
ofbroad spectrum antimicrobials in critical care. 
Evolving antibiotic susceptibility of nosocomial 
pathogens 
R.C. Spencer. P H U ,  Bristol, UK 
The emergence of antibiotic resistance in nosocomial pathogens 
continues to be an important c h c a l  problem. Gram-negative 
pathogens were more prevalent in the 1980s, and resistance has 
emerged to 3d generation cephalosporins (3GCs). quinolones and 
carbapenems. From the mid-1980s onwards, Gram-positive species 
have become more prevalent and resistance is increasing, particu- 
larly penicillin resistance in streptococci, methicillin resistance in 
staphylococci (up to 70% in coagulase-negative species causing ICU 
infections) and vancomycin resistance in enterococci. The reason for 
this increase is mulf3actorial, including inappropriate or overuse of 
broad-spectrum agents and increasing use of prosthetic materds and 
high-technology medicine. Widespread and sometimes indiscrimi- 
nate use of antibacterial agents has led to the development of mul- 
tiple drug resistance mechanisms. Faced with an alarming increase 
in resistance, rational use of antibacterials and appropriate mfec- 
tion control measures are of paramount importance. However, these 
measures can only work if supported by adequate surveillance data, 
particularly in the case of seriously ill patients where antibacterial 
therapy is mostly empirical. Surveillance must be performed at the 
local, national and international level. Most data on resistance preva- 
lence are inconsistent and hgmentary. In order to be useful, data 
should be generated by laboratories using reliable and reproducible 
testing methods, preferably reporting MICs or zone sizes, rather than 
susceptibility interpretations. In spite of the obvious problems that 
increasing resistance wiU cause, there are no formal collaborative 
surveillance studies in the developed world which will allow analysis 
of trends in resistance development. 
Clinical experience with 4th Generation 
cephalosporins in severe infections 
M. WOE. Hopital Bichnt-Claude Bernard, Paris, France 
Fourth generation cephalosporins (4GCs) are structurally related to 
3GCs but have advantages including improved membrane perme- 
ability, hgh stability and low &ty for /3-lactamases, and enhanced 
activity against Gram-positive pathogens. Only cefpirome and ce- 
fepime are widely available, but no direct comparisons have been 
made between the two. In severe infections, these agents have been 
shown to be both efficacious and safe, and at least as effective as 
ceftazidime. In ICU infections, cefpirome (n = 45) and ceftazidime 
(n = 52) gave similar clinical success rates (82% and 81% respec- 
tively. In febrile episodes in neutropenics (FNE), cefpirome and cef- 
tazidime were similar (92/127 vs 861119) although pathogens were 
more likely to be susceptible to cefpirome. Similarly, cefepime is as 
effective as ceftazidime or piperacilldgentamicin in FNE. In the 
treatment of nosocomial pneumonia, cefpirome is as effective as cef- 
tazidime, either as monotherapy (62% success for both antibiotics) or 
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in combination (62% vs 54%, respectively). The safety of 4GCs also 
seems similar to other cephalosporins: in reviews of 3103 patients 
treated with cefpirome and 2032 mated with cefepime, adverse 
events were recorded in 22% and 20.3% of patients, respectively. 
The most commonly-reported AEs are headache, nausea, diarrhea 
and vomiting. It is concluded that 4GCs are suitable agents for the 
treatment of severe n o s o c o d  infections, and show promise for the 
treatment of meningitis and paediatric infections. 
Evidence-based choice of antibiotic therapy in 
ambulatory practice 
The importance of clinical microbiology in 
ambulatory practice 
L.B. Reller. Duke University Medical Center, Durham, North Carolina, 
USA 
Objectives: To apply evidenced-based clinical microbiology to the 
management of upper and lower respiratory tract infections. 
Methods: By asking focused questions both practitioners as well as 
microbiologists can enhance the clinical value of microbiological tests 
for respiratory tract mfections. Why is the test being done? What re- 
sults can be expected? Will they be used to start ,  stop, or change ther- 
apy? Is there a simpler (and cheaper) approach? What are the implica- 
tions of not doing the test? What are the pitfaus of empirical therapy? 
Results: Most causes of nonexudative and exudative pharyngi- 
tis (adenovirus and Epstein-Barr virus) are viral. Cultures for group 
A smptococci are imperative if direct antigen tests are negative or 
if susceptibdxty testing is required owing to failures with antibiotics 
other than ,%lactams. Cultures rarely are required for acute otitis me- 
dia or sinusitis; complicated and chronic infections necessitate tym- 
panocentesis or direct aspirates. Cultures are not indicated for acute 
exacerbations of chronic bronchitis. To query pneumonias, sputum 
samples should be screened for quality (presence of neutrophils and 
absence of squamous epithelial cells) unless legionellosis or tuber- 
culosis is suspected. The gram-stained smear may suffice unless 
gram-negative bacilli and purulence are seen or penicillin-resistant 
pneumococci are sought. Cultures without Gram s t a i n s  defy inter- 
pretation. Many “atypical” pneumonias, includmg mycoplasma and 
chlamydia, are not routinely confirmed by laboratory testing. 
Conclusions: Microbiological investigations can be increased in 
value by asking appropriate questions and submitting only relevant 
specimens. 
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1s85) Molecular Biology of Prion Diseases 
C. Weissmann, A. Raeber, M. Fischer, A. Sailer, T. Riilicke’ ‘ Biologisches Zentrallabor, Univmitiitsspital Zurich, Switzerland 
The prion, the transmissible agent that causes mad cow disease and 
scrapie, is believed to be PrP*, a misfolded form of a normal host 
protein, PrPc, whch is found mainly in the central nervous system, 
but also in many other organs. PrPc is encoded by a single copy 
gene called plnp. The ‘)rolein only” hypothesis proposes that PrP’ 
propagates by causing conversion of PrPc into PrP’. We generated 
mice devoid of PrPc (“Prnp”” “) mice and found them to be totally 
resistant to scrapie and incapable of propagating prions. Introduction 
of PrP transgenes restored susceptibility to scrapie, paving the way to 
reverse genetics. We have prepared axumals transgenic for PrP genes 
with diverse mutations and determined which part ofthe molecule is 
important for susceptibility to scraspie. We have also introducing PrP 
genes controlled by promotors leading to overexpression in various 
tissues and have determined that expression of PrP in T cells is insuf- 
ficient to allow prion propagation, while expression in splenocytes is 
permissive, suggesting that other components may be required. Re- 
garding practical applications, we expect that cattle or sheep devoid 
of PrP genes should be resistant to scrapie; the knockout technology 
is however not yet available for cattle. 
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perception for the 21st century 
Trends in nosocomial infections in Europe 
(ESCMID Study Group on Nosocomial 
Infections) 
Is86/ Epidemiology of Nosocomial Infections in 
Europe: Can We Better? 
C. Ruef. University Hospital qfzurich, Zurich, Switzerland 
Nosocomial infections (NI )  are a burden to the health care systems of 
all European countries and often pose sigdicant problem for local 
providers of care. However, not irhequently, patients colonized or 
infected with nosocomial pathogens are transferred between coun- 
tries or regions. Therefore, the way NI are controlled, prevented 
or treated in one country m y  have consequences for the care of 
patients in other countries. 
Improved knowledge of the epidemiology of NI in Europe is 
needed in order to a) anticipate potential problems, i.e. associated 
with transfer of patients who are colonized or infected with muleire- 
sistant organisms; b) monitor the incidence and prevalence of noso- 
comial mfections; c) detect the epidemic spread of relevant pathogens 
(i.e. MRSA, penicillin-resistant pneumococci); d) locally improve the 
practice ofmfection control and infectious diseases by adapting meth- 
ods oflocal practice to procedures which have been shown to be suc- 
cessful in other countries. Sound and uniformly applied epldemiolog- 
ical methods are needed in order to obtain meaningful data on inci- 
dence and prevalence of nosocomial infections in various European 
countries. It wdl be necessary to coordmate national efforts on an in- 
ternauonal level. Such cooperations will likely be fi-uidul and result in 
a better acceptance of hospital epidemiology as a pro-active specialty 
which goes beyond the simple tabulation of infection rates. Such a 
pro-active approach will contribute to the continuous improvement 
